PharmaEssentia Wins FDA Approval for BESREMi in ET
BURLINGTON, Mass., August 31, 2026 PharmaEssentia announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon...
Biopharmaceuticals
Advertisement
Ascletis Starts Phase III Trial of Oral GLP-1 Drug
Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...
Amgen and AstraZeneca Report Positive Phase 3 EoE Data
Thousand Oaks, California, United States, Aug. 27, 2026 Amgen and AstraZeneca have announced positive top-line results from the Phase...
AbbVie Submits SKYRIZI SC Induction Application to EMA
North Chicago, Illinois, United States, Aug. 27, 2026 AbbVie has submitted a regulatory application to the European Medicines Agency...
Kowa Pharmaceuticals America Advances K-911 FDA Review
Montgomery, Alabama, United States, Aug. 27, 2026 Kowa Pharmaceuticals America, Inc. (KPA) announced that the U.S. Food and Drug...
Advertisements
Celcuity Files FDA sNDA for REVTORPYK in Breast Cancer
Minneapolis, Minnesota, United States, Aug. 26, 2026 Celcuity Inc., a biotechnology company developing targeted therapies for solid tumors, has...
Osivax, GC Biopharma Partner on Next-Gen Flu Vaccine
Lyon, France and Yongin, Republic of Korea, Aug. 26, 2026 Osivax, a clinical-stage biopharmaceutical company developing broad-spectrum influenza vaccines,...
Vanda Pharmaceuticals Gains EU Orphan Status for Imsidolimab
Washington, D.C., August 24, 2026 Vanda Pharmaceuticals Inc. announced that the European Commission has granted Orphan Designation to imsidolimab...
Harbour BioMed Wins NMPA IND Approval for HBM7004
Cambridge, Massachusetts; Rotterdam, Netherlands; and Shanghai, China, August 18, 2026 Harbour BioMed (HKEX: 02142) announced that China’s National Medical...
Kelun-Biotech Reports Strong H1 2026 Growth and Pipeline
CHENGDU, China — August 17, 2026 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) reported its unaudited interim results for the...
Advertisement
